Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-Transfected DC Vaccine in Advanced Malignant Melanoma
NCT01278940Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Mar 2002
- Primary completion
- Feb 2006
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
A Phase 2 trial of rocapuldencel-T in Malignant Melanoma (MM), sponsored by Oslo University Hospital. Started Mar 2002; status: completed.
02
Drugs
rocapuldencel-T
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01278940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01278940.